Term Name: acalabrutinib
Synonyms: (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide, 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide, 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide, acalabrutinib, acalabrutinibum, ACP-196, Calquence
Definition: A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Ontology: ChEBI [CHEBI:167707]  ( EBI )

Relationships
is a type of: aromatic amine benzamides imidazopyrazine pyridines pyrrolidinecarboxamide secondary carboxamide tertiary carboxamide ynone
has_role: antineoplastic agent apoptosis inducer EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor